DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathies Epidemiology Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.
The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of these cardiomyopathies segmented by subtype, sex, and age (under 18 years, 18-29 years, and by 10-year age groups for ages 30 years up to 80 years and older) in these markets. The diagnosed prevalent cases are further segmented by causes (acquired versus inherited) and ischemic cases (DCM only).
In the 7MM, the diagnosed prevalent cases of cardiomyopathies will increase from 2,268,240 cases in 2021 to 2,852,506 cases in 2031, at an annual growth rate (AGR) of 2.58% per year. The diagnosed prevalent cases of cardiomyopathies in the five major European markets (5EU) (France, Germany, Italy, Spain, and the UK) will increase at an AGR of 1.43%, from 366,582 cases in 2021 to 419,183 cases in 2031.
When examining the AGR by individual markets, the publisher estimates that the US will have the highest number of cases of cardiomyopathies in 2031, with 2,385,118 cases at an AGR of 2.87%. Conversely, Japan will have the least number of cases by 2031, with 48,205 cases at a negative AGR of 0.10%.
Scope
- The cardiomyopathies epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cardiomyopathies (DCM, HCM, RCM, and ARCM) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of cardiomyopathies segmented by subtype, sex, and age (under 18 years, 18-29 years, and by 10-year age groups for ages 30 years up to 80 years and older) in these markets. The diagnosed prevalent cases are further segmented by causes (acquired versus inherited) and ischemic cases (DCM only).
- The epidemiology report provides additional clinically relevant segmentations for the diagnosed prevalent cases of cardiomyopathies including subtype specific etiology
- The cardiomyopathies epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in cardiomyopathies.
The Cardiomyopathies Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global cardiomyopathies markets.
- Quantify patient populations in the global cardiomyopathies markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for cardiomyopathies therapeutics in each of the markets covered.
- Understand magnitude of the population with cardiomyopathies by age, sex, etiology, and ischemia (DCM only).
Key Topics Covered:
1 Cardiomyopathies: Executive Summary
1.1 Related Reports
1.2 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.1.1 Risk Factors and Comorbidities
2.2 Global and Historical Trends
2.3 Forecast Methodology
2.3.1 Sources
2.3.2 Forecast Assumptions and Methods
2.3.3 Diagnosed Prevalent Cases of Dilated Cardiomyopathy
2.3.4 Diagnosed Prevalent Cases of Hypertrophic Cardiomyopathy
2.3.5 Diagnosed Prevalent Cases of Restrictive Cardiomyopathy
2.3.6 Diagnosed Prevalent Cases of Arrhythmogenic Cardiomyopathy
2.3.7 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology
2.3.8 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia
2.4 Epidemiological Forecast for Cardiomyopathies (2021-2031)
2.4.1 Diagnosed Prevalent Cases of Cardiomyopathies
2.4.2 Diagnosed Prevalent Cases of Cardiomyopathies by Subtype
2.4.3 Age-Specific Diagnosed Prevalent Cases of Cardiomyopathies
2.4.4 Sex-Specific Diagnosed Prevalent Cases of Cardiomyopathies
2.4.5 Diagnosed Prevalent Cases of Cardiomyopathies by Etiology
2.4.6 Diagnosed Prevalent Cases of Dilated Cardiomyopathy with Ischemia
2.5 Discussion
2.5.1 Epidemiological Forecast Insight
2.5.2 COVID-19 Impact
2.5.3 Limitations of the Analysis
2.5.4 Strengths of the Analysis
3 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/b1efe2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
